Latest News
Poster 1025P presented at ESMO 2024
TILT Presents Clinical Data on TILT-123 After Fully Intravenous Delivery Regimen at ESMO 2024
TILT featured in an article by Tesi
TILT featured in ONCOLife June 2024 issue
Poster #433 presented at ASCO 2024. TILT-123 and pembrolizumab in ovarian cancer – Phase I data
Poster #137 presented at ASCO 2024. Intravenous delivery of TILT-123 – Phase I data
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024
TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024
TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense
Upcoming Events
Please contact our business development team to meet us at the following events:
11-13th December 2024
ESMO Immuno-Oncology Congress
Geneva, Switzerland
13-15th January 2025
Biotech Showcase
San Francisco (CA), USA